Background
Methods
Data retrieval strategy
Inclusion and exclusion criteria
Data extraction
Statistical analysis
Results
Eligible studies
Characteristics of analysed studies
No | First author | Year of Publication | Cases (n) | Country of origin | Ethnicity | Age (year) | Patient attributes | Diagnostic criteria | Drug | Follow-up period (weeks) |
---|---|---|---|---|---|---|---|---|---|---|
1 | Arranz et al. [11] | 1995 | 149 | USA | Caucasian | — | Schizophrenia | DSM-III-R | Clozapine | ≥ 12 |
2 | Malhotra et al. [18] | 1996 | 70 | USA | — | 30–44 | Schizophrenia or schizoaffective disorder | DSM-III-R | Clozapine | 10 |
3 | Masellis et al. [19] | 1998 | 181 | USA | Mixture | 24–42 | Schizophrenia | DSM-III-R | Clozapine | ≥ 24 |
4 | Lin et al. [10] | 1999 | 97 | China | East Asian | 34–41 | Schizophrenic disorders | DSM-IV | Clozapine | ≥ 8 |
5 | Joober et al. [20] | 1999 | 102 | Canada | Caucasian | 31–52 | Schizophrenia | DSM-IV | Clozapine | _ |
6 | Ellingrod et al. [6] | 2002 | 41 | USA | Caucasian | 18–65 | Schizophrenia | DSM-IV, BPRS 9 | Olanzapine | 6 |
7 | Mata-Pastor et al. [21] | 2002 | 51 | UK | Caucasian | 18–73 | Schizophrenia | DSM-IV | Olanzapine | ≥ 12 |
8 | Anttila et al. [22] | 2007 | 94 | Finland | Caucasian | 34–60 | Schizophrenia | DSM-IV | main Clozapine | 4 |
9 | Kim et al. [23] | 2008 | 100 | Korea | East Asian | 21–41 | Schizophrenia | DSM-IV | Risperidone | 4 |
10 | Thomas et al. [24] | 2008 | 115 | India | Indian | 18–65 | Schizophrenia or schizoaffective disorder | DSM-IV | Olanzapine | 6 |
11 | Olajossy-Hilkesberger et al. [25] | 2011 | 95 | Australia | Caucasian | 17–68 | Paranoid schizophrenia | DSM-IV | Olanzapine | ≥ 6 |
12 | Yan et al. (Shanghai) [9] | 2015 | 111 | China | East Asian | 18–60 | Schizophrenia | DSM-IV | Risperidone | 4 |
Yan et al. (Henan) [9] | 2015 | 87 | China | East Asian | 16–55 | Schizophrenia | DSM-IV | Risperidone | 4 | |
13 | Gareeva et al. [26] | 2015 | 97 | Russia | Russian | 15–54 | Paranoid schizophrenia | ICD-10 | Haloperidol | 3 |
14 | Kaur et al. [27] | 2017 | 331 | India | Indian | 18–55 | Schizophrenia | ICD-10 DCR | Risperidone | 12 |
15 | Shi et al. [28] | 2017 | 546 | China | East Asian | 19–51 | Schizophrenia | DSM-IV | Risperidone | 4 |
16 | Alladi et al. [8] | 2019 | 109 | India | Indian | 21–46 | Schizophrenia | Risperidone | 4 | |
17 | Yan et al. [29] | 2020 | 241 | China | East Asian | 18–60 | Schizophrenia | ICD-10 | Olanzapine | 4 |
18 | Maffioletti et al. (risperidone) [12] | 2020 | 121 | Italy | Caucasian | 28–54 | Schizophrenia | DSM-IV | Risperidone | 2 |
Maffioletti et al. (olanzapine) [12] | 2020 | 100 | Italy | Caucasian | 24–48 | Schizophrenia | DSM-IV | Olanzapine | 2 |
Study | Evaluation scale | Define responder | Allele | Genotype | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
T | C | TT | TC | CC | ||||||||
R | NR | R | NR | R | NR | R | NR | R | NR | |||
Arranz et al. 1995 [11] | GAS | GAS improvement > 20 | 84 | 36 | 100 | 78 | 15 | 9 | 54 | 18 | 23 | 30 |
Malhotra et al. 1996 [18] | BPRS | BPRS reduction ≥ 20% | 18 | 45 | 24 | 53 | 2 | 9 | 14 | 27 | 5 | 13 |
Masellis et al. 1998 [19] | BPRS | BPRS reduction ≥ 20% | 86 | 79 | 104 | 93 | 19 | 18 | 48 | 43 | 28 | 25 |
Joober et al. 1999 [20] | Priori criteria | _ | 31 | 38 | 47 | 88 | 7 | 7 | 17 | 24 | 15 | 32 |
Mata-Pastor et al. 2002 [21] | PANSS,GAS | GAS improvement > 20 | 24 | 22 | 32 | 24 | 6 | 3 | 12 | 16 | 10 | 4 |
Anttila et al. 2007 [22] | GGI | Hospital and mental health care records and personal interview | 29 | 27 | 57 | 73 | 3 | 4 | 23 | 19 | 17 | 27 |
Kim et al. 2008 [23] | GGI-I | GGI score < 4 | 74 | 22 | 92 | 12 | 13 | 6 | 48 | 10 | 22 | 1 |
Thomas et al. 2008 [24] | PANSS | PANSS reduction ≥ 30% | 75 | 61 | 59 | 35 | 17 | 15 | 41 | 31 | 9 | 2 |
Olajossy-Hilkesberger et al. 2011 [25] | PANSS | Total PANSS reduction ≥ 30% | 39 | 47 | 49 | 55 | 8 | 6 | 23 | 35 | 13 | 10 |
Kaur et al. 2017 [27] | PANSS | PANSS reduction rate ≥ 50% | 182 | 108 | 218 | 154 | 37 | 19 | 108 | 70 | 55 | 42 |
Shi et al. 2017 [28] | PANSS | PANSS reduction ≥ 50% | 386 | 230 | 308 | 168 | 110 | 66 | 166 | 98 | 71 | 35 |
Alladi et al. 2019 [8] | PANSS | PANSS reduction≧20% | 71 | 19 | 97 | 31 | 12 | 4 | 47 | 11 | 25 | 10 |
Yan et al. 2020 [29] | PANSS | PANSS reduction rate ≥ 50% | 173 | 117 | 117 | 75 | 51 | 39 | 71 | 39 | 23 | 18 |
Study | Cohort | Evaluation scale | Therapy efficiency | TT | TC | CC | |||
---|---|---|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | Mean | SD | ||||
Lin et al. 1999 [10] | - | BPRS | BPRS total score change | 8.7 | 1.2 | 9.5 | 1.1 | 8.6 | 1.9 |
Ellingrod et al. 2002 [6] | - | SANS | Reduction rate of SANS score | 46 | 12 | 20 | 6 | 20 | 6 |
Olajossy-Hilkesberger et al. 2011 [25] | - | PANSS | Reduction of total PANSS score | 28.7 | 20.9 | 22.3 | 18.8 | 33.4 | 18.5 |
Yan et al. 2015 [9] | Shanghai | PANSS | Reduction of total PANSS score | 24.98 | 15.47 | 24.73 | 13.62 | 19.72 | 10.96 |
Henan | PANSS | Reduction of total PANSS score | 17 | 16.08 | 20.21 | 17.97 | 19.94 | 15.05 | |
Gareeva et al. 2015 [26] | - | PANSS | Reduction rate of PANSS total score | 23.3 | 6.25 | 23.19 | 6.38 | 23.17 | 6.36 |
Alladi et al. 2019 [8] | - | PANSS | Reduction of PANSS score | 27.06 | 18.3 | 35.8 | 19.8 | 32.62 | 20.6 |
Maffioletti et al. 2020 [12] | Risperidone | PANSS | Reduction rate of total PANSS score | 27.1 | 11 | 21.7 | 10.9 | 23.2 | 12.7 |
Olanzapine | PANSS | Reduction rate of total PANSS score | 18.9 | 17.6 | 24.3 | 11.3 | 16.2 | 14.7 |
Meta-analysis
Meta-analysis of the relationship between rs6313 polymorphism and responder rate
Polymorphism | Total | Time | ||||||
---|---|---|---|---|---|---|---|---|
1995–2000 | 2001–2010 | 2011–2021 | ||||||
OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | |
T/C | 1.02[0.90,1.16] | 0.72 | 1.25[0.97,1.62] | 0.09 | 0.80[0.58,1.11] | 0.18 | 1.00[0.86,1.18] | 0.96 |
TT/TC | 0.93[0.74,1.16] | 0.50 | 0.81[0.49,1.35] | 0.42 | 0.84[0.47,1.50] | 0.56 | 0.98[0.75,1.29] | 0.91 |
TT/CC | 1.00[0.77,1.30] | 0.99 | 1.36[0.80,2.31] | 0.26 | 0.42[0.18,0.97] | 0.04 | 1.03[0.74,1.43] | 0.87 |
TC/CC | 1.12[0.78,1.59] | 0.54 | 1.70[0.88,3.29] | 0.11 | 0.52[0.15,1.75] | 0.29 | 1.04[0.75,1.43] | 0.83 |
Polymorphism | Ethnicity | Medicine | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
East Asian | Caucasian | Indian | Else | Risperidone | Olanzapine | Clozapine | ||||||||
OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | OR[95%CI] | P value | |
T/C | 0.88[0.72,1.07] | 0.20 | 1.32[1.02,1.72] | 0.04 | 1.07[0.83,1.37] | 0.59 | 0.95[0.66,1.36] | 0.78 | 0.98[0.82,1.17] | 0.80 | 0.88[0.68,1.13] | 0.31 | 1.27[1.00,1.61] | 0.05 |
TT/TC | 0.85[0.62,1.16] | 0.31 | 1.13[0.65,1.95] | 0.67 | 1.04[0.65,1.66] | 0.87 | 0.81[0.41,1.60] | 0.54 | 0.98[0.72,1.33] | 0.88 | 0.95[0.63,1.44] | 0.81 | 0.79[0.49,1.29] | 0.34 |
TT/CC | 0.79[0.53,1.18] | 0.25 | 1.56[0.88,2.79] | 0.13 | 1.11[0.64,1.94] | 0.70 | 0.86[0.40,1.85] | 0.71 | 0.93[0.64,1.35] | 0.69 | 0.82[0.47,1.44] | 0.49 | 13.4[0.81,2.22] | 0.26 |
TC/CC | 0.92[0.50,1.70] | 0.80 | 1.22[0.52,2.86] | 0.64 | 1.07[0.53,2.15] | 0.85 | 1.07[0.59,1.94] | 0.82 | 1.01[0.67,1.54] | 0.95 | 0.59[0.26,1.35] | 0.21 | 1.74[1.05,2.91] | 0.03 |
Meta-analysis of the relationship between the rs6313 polymorphism and scale score reduction rate
Polymorphism | Total | Time | ||||||
---|---|---|---|---|---|---|---|---|
1995–2000 | 2001–2010 | 2011–2021 | ||||||
SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | |
TT/TC | 0.16[-0.24,0.56] | 0.44 | -0.69[-0.98,-0.40] | 0.00 | 2.71[2.11,3.32] | 0.00 | -0.02[-0.28,0.24] | 0.87 |
TT/CC | 0.27[-0.07,0.61] | 0.12 | 0.06[-0.22,0.34] | 0.66 | 2.71[2.11,3.32] | 0.00 | 0.03[-0.18,0.24] | 0.77 |
TC/CC | 0.12[-0.13,0.37] | 0.35 | 0.58[0.29,0.86] | 0.00 | 0.00[-0.43,0.43] | 1.00 | 0.07[-0.21,0.35] | 0.63 |
Polymorphism | Ethnicity | Medicine | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
East Asian | Caucasian | Indian | Russian | Risperdone | Olanzapine | Clozapine | Haloperidol | |||||||||
SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | SMD[95%CI] | P value | |
TT/TC | -0.28[-0.70,0.13] | 0.18 | 0.74[-0.10,1.59] | 0.08 | -0.46[-0.73,-0.19] | 0.00 | 0.02[-0.26,0.30] | 0.90 | -0.03[-0.44,0.37] | 0.88 | 0.86[-0.45,2.16] | 0.20 | -0.69[-0.98,-0.40] | 0.00 | 0.02[-0.26,0.30] | 0.90 |
TT/CC | 0.09[-0.24,0.42] | 0.58 | 0.69[-0.10,1.48] | 0.09 | -0.28[-0.55,-0.02] | 0.04 | 0.02[-0.26,0.30] | 0.89 | 0.06[-0.28,0.41] | 0.71 | 0.84[-0.40,2.09] | 0.18 | 0.06[-0.22,0.34] | 0.66 | 0.02[-0.26,0.30] | 0.89 |
TC/CC | 0.34[0.02,0.65] | 0.04 | -0.03[-0.54,0.49] | 0.92 | 0.16[-0.11,0.42] | 0.25 | 0.00[-0.28,0.28] | 0.98 | 0.11[-0.12,0.34] | 0.33 | 0.01[-0.77,0.79] | 0.98 | 0.58[0.29,0.86] | 0.00 | 0.00[-0.28,0.28] | 0.98 |